600252.SH
中恒集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 2.18
−1.80%Year over year
Reported trailing growth
- Revenue
- -15.2%
- EBITDA
- —
- EBIT
- +0.1%
- EPS
- -6.4%
- Free cash flow
- -89.9%
- Operating cash flow
- -81.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.6%
- EBITDA
- -3.3%
- EBIT
- -0.2%
- Net income
- +5.3%
- EPS
- -2.2%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026